At Sorin, we look to back companies solving large, structurally broken problems with a clear path to building category leadership. Chronic pain management in India is one such market - affecting nearly 1 in 5 adults, yet largely addressed through fragmented care, prolonged physiotherapy, or (in some cases) avoidable surgeries. Despite the scale of the problem, India lacks a dedicated, standardized platform for modern, comprehensive pain treatment methodology prevalent in developed countries.
Nivaan Care is building exactly that - with a patient-first philosophy anchored in measurable clinical outcomes.
A large market with a clear care gap
India has an estimated ~270 million chronic pain patients, many of whom cycle through multiple doctors over several years before finding relief. While minimally invasive pain procedures are globally established, they remain underutilized in India due to low awareness and poor incentivisation within multispecialty set ups. Although many anaesthesiologists are trained in pain medicine, the lack of dedicated care models and incentives has kept pain management from scaling as a standalone specialty. This creates a large whitespace between physiotherapy and surgery - one that Nivaan squarely addresses.
Deep clinical expertise, institutionalised
What differentiated Nivaan early for us was its clinically-led approach to scale. The company has built one of the largest multidisciplinary pain teams in the country, bringing together pain physicians and physiotherapists under a unified care model.
Nivaan has standardized protocols for triaging patients, identifying the right procedure from a spectrum of treatment options, and delivering targeted interventions such as radiofrequency ablation, nerve blocks, and regenerative therapies like PRP; This enables consistent outcomes across clinics. Notably, advanced therapies already contribute over a third of procedures by volume, and early patient data shows ~50% average pain reduction, with many patients avoiding surgery altogether.
Equally important, Nivaan is investing in clinical R&D and evidence generation - including India’s first standardized PRP protocols - which we believe is critical for continued insurance adoption as new protocols emerge, building category credibility, and reinforcing an outcomes-driven culture at scale..
Early traction with a repeatable operating playbook
Founded in early 2023, Nivaan has expanded across key urban markets in Delhi NCR and Mumbai, completing 40,000+ consultations and 5,000+ minimally invasive procedures. Several mature clinics are already operating at profitable unit economics, validating the playbook.
A founder team built for healthcare execution
The founding team brings a rare combination of healthcare delivery within single-specialty set ups, P&L ownership, and platform-building experience, complemented by senior clinicians with decades of practice. Together, they envision building long-term patient trust by delivering clinically right solution. Their ability to marry clinical excellence with scalable execution gives us confidence in Nivaan’s ability to build a durable institution, not just a network of clinics.
We believe Nivaan has the potential to define modern pain management in India, setting new benchmarks for outcomes, accessibility, and clinical rigor. We’re excited to partner with the team as they scale across cities and expand the scope of evidence-based, minimally invasive care for millions of patients.